Compare VOC & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VOC | KRRO |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 105.0M |
| IPO Year | N/A | 2019 |
| Metric | VOC | KRRO |
|---|---|---|
| Price | $3.56 | $12.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $47.10 |
| AVG Volume (30 Days) | ★ 129.9K | 125.9K |
| Earning Date | 01-01-0001 | 06-17-2026 |
| Dividend Yield | ★ 11.50% | N/A |
| EPS Growth | N/A | ★ 82.35 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,271,000.00 |
| Revenue This Year | N/A | $145.97 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.44 | $5.20 |
| 52 Week High | $3.74 | $55.89 |
| Indicator | VOC | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 67.46 | 57.50 |
| Support Level | $2.73 | $12.17 |
| Resistance Level | N/A | $12.54 |
| Average True Range (ATR) | 0.20 | 0.80 |
| MACD | 0.05 | -0.07 |
| Stochastic Oscillator | 71.91 | 77.81 |
VOC Energy Trust is a statutory trust. It is created to acquire and hold a term net profits interest for the benefit of the Trust unitholders. The underlying properties include VOC Brazos' net interests which are located in the states of Kansas and Texas. The trust is entitled to receive the net proceeds from the sale of production of oil and natural gas attributable to the underlying properties. The business and affairs of the Trust are managed by the Trustee, and neither VOC Brazos nor any of its affiliates has the ability to manage or influence the operations of the Trust.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.